Heart failure & cardiomyopathies
Heart Failure Risk Scores in Advanced Heart Failure Patients: Insights from the LEVO-D Registry
Authors' conclusion
The two evaluated risk scores showed suboptimal discrimination and calibration with an underestimation of risk in advanced HF patients receiving levosimendan as destination therapy.
Study context
- Population
- Advanced heart failure (HF) patients receiving intermittent inotropic support with levosimendan as destination therapy
- Participants
- 403 patients23 hospitals
- Comparison
- BCN-Bio-HF vs Meta-Analysis Global Group in Chronic HF (MAGGIC-HF) risk scores
- Outcome
- Discrimination for all-cause mortality (AUC and Harrell's C-statistic)
- Follow-up
- 1 year
Methodological detailsmulticentre, 23 tertiary hospitals in Spain
- Multicentre
- 23 tertiary hospitals in Spain
Performance
As reported in the abstract
All-cause mortality prediction
| Test or model | AUC | Harrell's C-statistic | Predicted 1-year mortality |
|---|---|---|---|
| BCN-Bio-HF | 0.66 | 0.64 | 17.0% |
| MAGGIC-HF | 0.62 | 0.61 | 22.1% |
AUC
BCN-Bio-HF0.66
MAGGIC-HF0.62
Harrell's C-statistic
BCN-Bio-HF0.64
MAGGIC-HF0.61
Predicted 1-year mortality
BCN-Bio-HF17.0%
MAGGIC-HF22.1%
- Observed death rate at 1 year
- 26.8%
Original publication
Heart Failure Risk Scores in Advanced Heart Failure Patients: Insights from the LEVO-D Registry. ESC Heart Fail. Published 8 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →